FHL has acquired an exclusive license on 4 drug pipeline
FHL has acquired an exclusive license on 4 drug pipeline targeting Parkinson’s disease and Alzheimer’s disease.
Curyx Bio Inc.(“CB”) is a US-based biopharmaceutical company developing novel drugs for treating neurodegenerative disorders including Parkinson’s Disease (“PD”), Alzheimer’s disease (“AD”), Dementia with Lewy Bodies (“DLB”), Huntington’s Disease (“HD”), and Glycine Encephalopathy (“GE”).
FHL has entered into an exclusive in-license agreement on 4 drug pipeline, FHL CB101, FHL CB201, FHL CB301, FHL CB401 targeting Parkinson’s Disease (“PD”) and Alzheimer’s disease (“AD”).
Strategic decision has been made to focus on expanding healthcare market based on the increasing number of patients in aging world including China, Korea and the other countries.
If you are interested in it and want to know more about the details, please visit our THERAPEUTIC page for more information.